The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
BIOHAVEN PHARMACTL HLDG CO L COM G11196105 153,122 1,111,111 SH   DFND 1 1,111,111 0 0
VIRACTA THERAPEUTICS INC COM 92765F108 13,505 3,700 SH   DFND 1 3,700 0 0
EPIZYME INC COM 29428V104 22,917 9,166,667 SH   DFND 1 9,166,667 0 0
EPIZYME INC COM 29428V904 6,365 2,546,134 SH Call DFND 1 2,546,134 0 0
BIOCRYST PHARMACEUTICALS INC COM 09058V103 43,000 3,846,154 SH   DFND 1 3,846,154 0 0